Company intelligence / Profile preview

Corsair Productions

Newark, Sunnyvale, California, United Statescorsairproductions.net ↗

Ownership: Private
Development stage: Other

Overview

Corsair Pharma has completed preclinical studies demonstrating positive results with its TRX-248 Treprostinil Prodrug Transdermal System. The company is preparing to initiate a Phase 1 clinical trial in the second quarter of 2025. The product aims to provide steady, continuous blood levels of treprostinil via a once-daily transdermal patch, potentially improving efficacy and side effect profile compared to current therapies.

Therapeutic areas: Cardiovascular
Modalities: Small moleculeProdrugTransdermal patch delivery system
Industry: Biotech

Partnerships

United Therapeutics (strategic collaboration on novel treprostinil prodrugs)

Beyond the preview

Go deeper on Corsair Productions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corsair Productions.

Explore the full profile